Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success

T IF koto_feja Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) focuses on targeted immunotherapies for solid tumors. The company's flagship drug candidate is Cosibelimab, a novel anti-PD-L1 antibody currently under FDA review for treating cutaneous squamous cell carcinoma [cSCC] as a single-agent therapy. Cosibelimab could potentially have indications for metastatic cSCC and locally advanced cSCC. Additionally, it has a dual mechanism of action with NK cells that gives it a theoretical edge over other PDL1 inhi ...